MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

The influence of Caffeine intake on Type 2 Diabetes Mellitus mediated risk of Parkinson’s Disease.

K. Mallavarapu, E. Tan (Singapore, Singapore)

Meeting: 2025 International Congress

Keywords: Caffeine, Parkinson’s

Category: Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales

Objective: The objectives are to investigate if a diagnosis of Type 2 Diabetes Mellitus (T2DM) is associated with increased risk of developing Parkinson’s Disease (PD) and to explore if caffeine intake attenuates the increased PD risk associated with T2DM.

Background: T2DM has been postulated as a potential risk factor for PD, given the common mechanisms of dysregulation in both. Studies, however, show conflicting evidence pertaining to the presence and magnitude of risk. Caffeine has been associated with reduced risk of PD with underlying gene-lifestyle interaction. It is yet to be determined if T2DM increases the risk of PD and if caffeine intake is able to attenuate this increased risk.

Method: A case-control study was conducted, involving 1395 PD patients and 2421 healthy subjects. Family history of PD, T2DM status and caffeine consumption were recorded using a validated questionnaire. Univariate and multivariable logistic regression analyses were performed to assess the association between T2DM status and PD risk. Subgroup analyses were done after stratifying for T2DM and caffeine intake status.

Results: Individuals with T2DM are 4.51 more likely to develop PD than those without (OR = 4.51, 95% CI: (3.62, 5.66), p = <2×10−16). Multivariable logistic regression with adjustment for covariates revealed that individuals with T2DM were 2.33 times more likely to develop PD compared to those without (OR = 2.33, 95% CI: (1.79, 3.03), p = 2.38×10-10). Amongst diabetic individuals, caffeine intake was associated with 78% reduction in PD risk (OR = 0.22, 95% CI: (0.03, 0.76), p = 0.04229). When compared to healthy individuals who consume caffeine, diabetic individuals who do not consume caffeine were found to be 11.43 times more likely to develop PD (OR = 11.43, 95% CI: (3.01, 75.06), p = 0.00179).

Conclusion: T2DM is associated with a statistically significant increased risk of developing PD. This study unveils that a diabetic individual who does not consume caffeine may be about 11 times more likely to develop PD when compared to a healthy individual who consumes caffeine. These findings advocate for caffeine intake to be adopted as a lifestyle modification or therapeutic agent, especially in populations at higher risk for PD.

To cite this abstract in AMA style:

K. Mallavarapu, E. Tan. The influence of Caffeine intake on Type 2 Diabetes Mellitus mediated risk of Parkinson’s Disease. [abstract]. Mov Disord. 2025; 40 (suppl 1). https://www.mdsabstracts.org/abstract/the-influence-of-caffeine-intake-on-type-2-diabetes-mellitus-mediated-risk-of-parkinsons-disease/. Accessed October 5, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2025 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/the-influence-of-caffeine-intake-on-type-2-diabetes-mellitus-mediated-risk-of-parkinsons-disease/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • AI-Powered Detection of Freezing of Gait Using Wearable Sensor Data in Patients with Parkinson’s Disease
  • Effect of Ketone Ester Supplementation on Motor and Non-Motor symptoms in Parkinson's Disease
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Insulin dependent diabetes and hand tremor
  • Improvement in hand tremor following carpal tunnel release surgery
  • Impact of expiratory muscle strength training (EMST) on phonatory performance in Parkinson's patients
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley